{"id":"W4392229930","doi":"10.1200/jco.23.02744","title":"Therapy for Stage IV Non–Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2023.3","year":2024,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":55,"is_retracted":false,"has_abstract":true,"ca_institutions":"London Health Sciences Centre; Princess Margaret Cancer Centre; University Health Network","funders":"Astellas Pharma; Eisai; G1 Therapeutics; NGM Biopharmaceuticals; Tarveda Therapeutics; Moderna; Pfizer; Incyte; Agios Pharmaceuticals; BeiGene; Mirati Therapeutics; GlaxoSmithKline; Tizona Therapeutics; Clovis Oncology; Daiichi Sankyo Europe; Gilead Sciences; Calithera Biosciences; AstraZeneca; Novocure; MacroGenics; Celldex Therapeutics; Ipsen; Jazz Pharmaceuticals; Regeneron Pharmaceuticals; Merck KGaA; Apollomics; Sanofi; Bristol-Myers Squibb; Eli Lilly and Company; American Society of Clinical Oncology; Genentech; Aeglea BioTherapeutics; Amgen; Celgene","keywords":"Guideline; Medicine; Randomized controlled trial; Systematic review; Family medicine; Evidence-based practice; MEDLINE; Alternative medicine; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004706677,0.0008378616,0.001596124,0.003235853,0.0006210385,0.001729294,0.002399473,0.003683054,0.006749454],"category_scores_gemma":[0.01893254,0.0005586838,0.004114937,0.002950044,0.0004246609,0.001443289,0.001319735,0.002910135,0.00505697],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.002756899,"about_ca_system_score_gemma":0.009437328,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.02337676,"about_ca_topic_score_gemma":0.06655764,"domain_scores_codex":[0.9955534,0.001209037,0.001235706,0.0002020415,0.001520078,0.0002797202],"domain_scores_gemma":[0.9917871,0.002014741,0.001361497,0.0002058025,0.00422107,0.0004096732],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0000830339,0.00005769698,0.001970244,0.01147346,0.0004193466,0.0001349741,0.0001038093,0.0005453391,0.0006774772,0.00145156,0.8325515,0.1505315],"study_design_scores_gemma":[0.0005776363,0.0001618231,0.008711404,0.04752137,0.001562514,0.0005907844,0.0001565732,0.0007773095,0.0006439821,0.00412259,0.9350859,0.0000879956],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.009914312,0.4230114,0.04184854,0.2060918,0.02075021,0.01660467,0.1391695,0.003476223,0.1391333],"genre_scores_gemma":[0.04654227,0.3846579,0.1692804,0.1523209,0.006639198,0.0195515,0.1608149,0.001181845,0.05901114],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.02337676,"threshold_uncertainty_score":0.04648137,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1387619730936928,"score_gpt":0.5291187612858572,"score_spread":0.3903567881921645,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}